Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp has demonstrated a stronger correlation in its clinical trial results, highlighted by an increase in the ABCLEAR32 population's ADAS-Cog13 R2 value from 0.23 to 0.41, aligning with the company's precision medicine strategy for CNS disorders. The company is actively engaging with regulatory bodies, including the FDA and EMA, to enhance prospects for multiple indications, including Alzheimer's and Parkinson's diseases, while maintaining a flexible approach that preserves credibility. Furthermore, ongoing iterative discussions with regulators are expected to advance Anavex's biomarker-driven narrative towards a viable approval path, underscoring the potential for significant growth as the company develops treatments for various neurodegenerative and neurodevelopmental diseases.

Bears say

Anavex Life Sciences Corp has reduced the likelihood of success for its therapeutic models in the U.S. to 50% and the EU to 15%, reflecting increased concerns regarding the viability of its drug development efforts. The company has also withdrawn its marketing application for blarcamesine in early Alzheimer's disease due to unfavorable feedback from the European Medicines Agency (EMA), opting to regroup for a potential resubmission in the future. This strategic setback underscores the challenges the company faces in advancing its clinical pipeline, raising questions about its ability to successfully navigate regulatory processes and meet market expectations.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.